skip to content

Roche to present new OCREVUS (ocrelizumab) data analyses showing significant reduction of disability progression in relapsing and primary progressive multiple sclerosis at the AAN Annual Meeting

Media

Media releases
view all

stay updated

get the latest news and updates to your inbox.